Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_4
1
17%
Ph phase_3
2
33%
Ph not_applicable
1
17%
Ph phase_2
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completednot_applicable

Sex-Differential Health Interventions In Low-Birth-Weight Infants

NCT00625482
completedphase_4

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

NCT02408926
completedphase_3

Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

NCT02062385
completedphase_2

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

NCT01231503
completed

Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine

NCT02643446
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00625482Not Applicable

Sex-Differential Health Interventions In Low-Birth-Weight Infants

Completed
NCT02408926Phase 4

Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand

Completed
NCT02062385Phase 3

Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

Completed
NCT01231503Phase 2

Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants

Completed
NCT02643446

Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine

Completed
NCT01457560Phase 3

Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6